Cancer Vaccine Company DCPrime and Janssen To Collaborate on Potential New Therapy DCPrime

By a News Reporter-Staff News Editor at Cancer Vaccine Week -- Cancer vaccine company DCPrime BV announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals, Inc. The collaboration has been facilitated in conjunction with the Johnson & Johnson London Innovation Centre, where a team of business, science and transaction experts are identifying and building novel early-stage collaborations with emerging companies (see also DCPrime).

Under the agreement, Janssen will utilize DCPrime's DCOne™ technology in feasibility studies for the development of a dendritic cell-based vaccine. Additionally, Janssen will have the option to further develop a candidate therapeutic towards regulatory approval.

"DCPrime is always looking for new opportunities for our DCOne technology," said Marcel Zwaal, CEO of DCPrime. "We are very excited to be able to work with Janssen and it will enable us to further extend the use our vaccine products." About DCPrime DCPrime develops off-the-shelf dendritic cell-based vaccines for a broad range of cancer types, based on its unique, proprietary technology platform, DCOne™. DCOne-based dendritic cell vaccines, in some indications loaded with cancer antigens for targeted treatment, will be used as standardized, therapeutic products. The platform combines the power of dendritic cell-based vaccines with the advantages of allogeneic stimulation of the immune system, and the simple logistics of off-the-shelf products. DCPrime has successfully completed a Phase I/IIa study in AML and has developed a commercial scale manufacturing process for DCOne-based vaccines.

Keywords for this news article include: Antigen-Presenting Cells, Pharmaceuticals, DCPrime, Therapy, Oncology, Immunology, Technology, Cancer Vaccines, Dendritic Cells, Biological Products, Clinical Trials and Studies, Mononuclear Phagocyte System.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC